Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kalaris Therapeutics ( (KLRS) ) just unveiled an announcement.
Kalaris Therapeutics announced on December 17, 2025, positive initial data from its Phase 1a clinical trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). The trial showed significant improvements in visual acuity and retinal anatomy, with a mean 10-letter gain in vision and robust reductions in central subfield thickness and fluid, following a single injection. TH103 was generally well-tolerated, with no serious adverse events or dose-limiting toxicities observed, and additional process improvements eradicated earlier instances of mild inflammation. This data supports TH103’s engineered extended intraocular retention and suggests the potential for reduced treatment burden and extended treatment durability, positioning the therapy as a promising advancement in the management of nAMD.
The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.
Spark’s Take on KLRS Stock
According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.
AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.
To see Spark’s full report on KLRS stock, click here.
More about Kalaris Therapeutics
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for retinal diseases, particularly those with significant unmet medical needs such as neovascular age-related macular degeneration (nAMD). Founded by Dr. Napoleone Ferrara, a pioneer in anti-VEGF therapy, the company leverages innovative approaches to address prevalent retinal conditions.
Average Trading Volume: 165,810
Technical Sentiment Signal: Hold
Current Market Cap: $144.9M
For an in-depth examination of KLRS stock, go to TipRanks’ Overview page.